Table 2 Transition probabilities from the decision tree to the Markov model
Parameter | Transition probability (Palivizumab and no prophylaxis) | Calculation (see Table 1 for efficacy inputs) |
|---|---|---|
MA-RSV | ||
No sequelae, % | 56.1 | (1 − p Asthma ) × (1 − p AS ) |
Asthma, % | 6.4 | p Asthma × (1 − p AS ) |
Allergic sensitization, % | 33.6 | (1 − p Asthma ) × p AS |
Asthma and allergic sensitization, % | 3.9 | p Asthma × p AS |
RSV-H | ||
No sequelae, % | 38.1 | (1 − p Asthma ) × (1 − p AS ) |
Asthma, % | 18.4 | p Asthma × (1 − p AS ) |
Allergic sensitization, % | 29.3 | (1 − p Asthma ) × p AS |
Asthma and allergic sensitization, % | 14.2 | p Asthma × p AS |